Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 12/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900782 | 0.98 | MPO (0.47) | MPODGAT1ACHEGRIA2NTRK1 | |
| SCHEMBL12984693 | 0.94 | MPO (0.40) | MPODGAT1ACHEGRIA2NTRK1 | |
| SCHEMBL17979144 | 0.87 | MPO (0.37) | MPODGAT1GRIA2NTRK1 | |
| SCHEMBL13955092 | 0.87 | MPO (0.39) | MPOGRIA2 | |
| SCHEMBL13598338 | 0.84 | MPO (0.46) | MPODGAT1ACHENTRK1ABL1 | |
| SCHEMBL13598336 | 0.83 | MPO (0.47) | MPODGAT1ACHENTRK1ABL1 | |
| SCHEMBL13195465 | 0.78 | MPO (0.42) | MPODGAT1NTRK1 | |
| SCHEMBL18018477 | 0.76 | MPO (0.43) | MPODGAT1ACHENTRK1ABL1 | |
| SCHEMBL3684845 | 0.76 | GPR119 (0.38) | DGAT1GRIA2 | |
| SCHEMBL12985784 | 0.76 | NTRK1 (0.42) | MPODGAT1ACHENTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | S1PR3, S1PR2, S1PR1 | MPO 4208/4885DGAT1 498/4885ACHE 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.